Nanomedicine efficacy in a clinical setting depends on the pharmacological properties of the therapeutic nanoparticles. Here, the authors exemplify an accelerated translational strategy from small-scale screening to clinical scale-up for an orally-dosed aqueous paediatric HIV nanomedicine.
- Marco Giardiello
- Neill J. Liptrott
- Andrew Owen
